MENU
+Compare
HROW
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$28.95
Change
-$1.18 (-3.92%)
Capitalization
467.85M

HROW Harrow Forecast, Technical & Fundamental Analysis

a pharmaceutical company

HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for HROW with price predictions
Feb 18, 2025

HROW's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for HROW turned positive on February 10, 2025. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Oscillator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where HROW's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 18, 2025. You may want to consider a long position or call options on HROW as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HROW entered a downward trend on February 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HROW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.398) is normal, around the industry mean (59.679). P/E Ratio (39.526) is within average values for comparable stocks, (89.540). HROW's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (3.207) is also within normal values, averaging (19.827).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

HROW is expected to report earnings to fall 210.42% to 13 cents per share on March 13

Harrow HROW Stock Earnings Reports
Q4'24
Est.
$0.13
Q3'24
Missed
by $0.07
Q2'24
Beat
by $0.12
Q1'24
Missed
by $0.08
Q4'23
Missed
by $0.22
The last earnings report on November 13 showed earnings per share of -11 cents, missing the estimate of -5 cents. With 584.87K shares outstanding, the current market capitalization sits at 467.85M.
A.I. Advisor
published General Information

General Information

a pharmaceutical company

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
102 Woodmont Boulevard
Phone
+1 615 733-4730
Employees
315
Web
https://www.harrow.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

HROW and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+0.49%
AMRX - HROW
33%
Loosely correlated
+0.78%
ORGO - HROW
29%
Poorly correlated
-1.35%
RMTI - HROW
27%
Poorly correlated
+2.70%
EBS - HROW
25%
Poorly correlated
-14.20%
AMPH - HROW
24%
Poorly correlated
-0.87%
More